News
Phase 2, with a gross development value of £41.5m, will add 120 student beds, bringing the total to 419 beds across both ...
PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA ...
1h
Cryptopolitan on MSNBest Entry Point This Month: The Only Sub-$0.05 Crypto With a Clear 400% TrajectoryAt just $0.03 per token, Mutuum Finance (MUTM) is attracting serious attention from DeFi investors looking to capture ...
Delhi University on Tuesday, July 8, opened Phase 2 of its Common Seat Allocation System (CSAS) for Undergraduate Admissions ...
Over 2.65 lakh candidates have registered on the CSAS portal as the second phase kicks off. Read the full article to know the ...
Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...
NASA’s SLS rocket and Orion programs received significant funding after previously being on the chopping block for NASA budget cuts.
Duality Biotherapeutics' ('DualityBio', HKEX:09606) partner Avenzo Therapeutics, Inc. ('Avenzo'), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced ...
The City of Rochester is ready to move into the last phase of the construction of its skate park. The city is looking for ...
Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...
The University of Delhi has started the second phase of DU UG Admission registration on July 8, 2025, with applications ...
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results